SRC and acute lymphoblastic leukemia: Dasatinib is a second-generation TKI with dual ABL/SRC kinase inhibition activity approved by both the FDA and EMA for the treatment of pediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.